ライフサイエンスコーパス: bone density

1 nosine A(1) receptor blockade or deletion on bone density.

2 rovide a comprehensive synopsis of pediatric bone density.

3 ts of weight lifting, including increases in bone density.

4 ion in the growth plate and lower trabecular bone density.

5 nitoring of serum calcium concentrations and bone density.

6 were adjusted for age, sex, knee injury, and bone density.

7 , decreasing bone resorption, and increasing bone density.

8 treatment regimen, and weight, could predict bone density.

9 bolic acidosis may have a negative effect on bone density.

10 0 dollars, depending on age and femoral neck bone density.

11 sessed for alveolar crestal height (ACH) and bone density.

12 ometric analysis including new bone area and bone density.

13 tropic effects on body fat, lipid levels and bone density.

14 in mice with skeletal dwarfism and decreased bone density.

15 steoclast numbers and, additionally, loss of bone density.

16 kinky hair, thin-pitted enamel and increased bone density.

17 screening method for assessment of skeletal bone density.

18 d strains of mice regulate bone strength and bone density.

19 could benefit from intervention to increase bone density.

20 ous activity and phosphaturia with decreased bone density.

21 bitor of angiogenesis and known regulator of bone density.

22 in adult bone, is a negative determinant of bone density.

23 every 12 weeks, regardless of pretransplant bone density.

24 no difference in hypertension or diabetes or bone density.

25 lated as a percentage relative to the native bone density.

26 molecular explanation for abnormal increased bone density.

27 cognitive and behavioral impairments and low bone density.

28 or source of dietary flavonoids, with higher bone density.

29 e pathophysiology of nephrolithiasis and low bone density.

30 tures suggesting a positive role of GPR40 on bone density.

31 s result in van Buchem disease with elevated bone density.

32 resorption of bone that results in increased bone density.

33 able, display chondrodysplasia and decreased bone density.

34 stronger as were those between VAT and lower bone densities.

35 rea, 35.8 +/- 3.6 versus 30.1 +/- 2.2 mm(2); bone density, 31.8% +/- 1.6% versus 35.6% +/- 2.5%; and

36 omal dominant syndrome characterized by high bone density, a wide and deep mandible, and torus palati

37 vertical bite-wings were taken for alveolar bone density (ABD) and alveolar bone height (ABH) measur

38 r vertical bitewings were taken for alveolar bone density (ABD) and alveolar bone height (ABH) measur

39 s of vitamin A (retinol), on post-natal peak bone density acquisition and skeletal remodeling are com

40 However, mean bone densities actually increased slightly in the entire

41 (mean +/- SD) 4.9 +/- 3.0% and 2.8 +/- 3.2% bone density after 1 year versus placebo, which lost (me

42 the use of bisphosphonates for retention of bone density after joint replacement.

43 f 945 women were previously unaware of their bone density, although, for 344 (36.4%), osteoporosis wa

44 Fractures to estimate risk of fracture from bone density and age in postmenopausal women.

45 in a gradual loss of effect, as measured by bone density and biochemical markers of bone remodeling.

46 The corresponding bone density and bone-implant contact registrations aver

47 the strongest associations between systemic bone density and CAL among women without subgingival cal

48 trimental effects of ovarian hormone loss on bone density and cardiovascular health.

49 investigating associations between systemic bone density and clinical attachment loss (CAL) of the s

50 /-) mice does not normalize mass, length, or bone density and content in fgf21(-/-)ksr2(-/-) mice.

51 ny postmenopausal women are unaware of their bone density and could benefit from screening.

52 eiving ADT, once-weekly alendronate improves bone density and decreases turnover.

53 association of magnesium and potassium with bone density and demonstrate that further investigation

54 e in Scd-1 expression, and 10.6% increase in bone density and entirely lacked the alopecia phenotype

55 etic bone disease characterized by increased bone density and fragility.

56 ave advantages, including the maintenance of bone density and high concentrations of growth factors.

57 In addition, bone density and histology revealed no differences betwe

58 g genetic component characterized by reduced bone density and increased fracture risk.

59 low vitamin K intake has been related to low bone density and increased risk of osteoporotic fracture

60 ence was associated with increased vertebral bone density and increased whole-body bone dimensions an

61 ades, they have also been suffering from low bone density and its clinical manifestations, fractures

62 s raise the possibility that the increase in bone density and loss of cartilage that are characterist

63 le acting as an estrogen agonist to maintain bone density and lower serum cholesterol.

64 e Aldh1a1 as a novel determinant of cortical bone density and marrow adiposity in the skeleton in viv

65 in hormone levels during menopause decrease bone density and may worsen oral health, favoring the gr

66 Systemic bone density and oral infection independently influenced

67 ns (ACP) recommendations on treatment of low bone density and osteoporosis to prevent fractures in me

68 t population includes men and women with low bone density and osteoporosis.

69 Other outcomes, including bone density and other serum lipid levels, did not chang

70 Low bone density and previous fractures are risk factors for

71 y; cause gastrointestinal problems; decrease bone density and production of blood cells; and cause fe

72 actions in other tissues, acting to promote bone density and protect against cardiovascular disease,

73 is, physicians should assess their patients' bone density and provide preventive and therapeutic meas

74 to quantitative imaging techniques measuring bone density and quality, imaging needs to be used to di

75 idence suggests that it can increase femoral bone density and reduce fracture risk.

76 Nox4(-/-) mice displayed higher bone density and reduced numbers and markers of osteocla

77 ether peripheral serotonin has any effect on bone density and remodeling.We therefore decided to inve

78 relationship between various measurements of bone density and risk of vertebral and hip fracture.

79 macologic inhibitors of this enzyme improved bone density and strength in two rodent models of osteop

80 ture risk and identify strategies to improve bone density and structure.

81 AC5 KO mice are protected from reduced bone density and susceptibility to fractures of aging.

82 tionships between maxillary alveolar process bone density and the density of the mandibular alveolar

83 still an association between the decline in bone density and the number of puffs per year of use.

84 Low bone density and the occurrence of vertebral fractures i

85 to determine whether regional variations in bone density and trabecular architecture in relation to

86 was anabolic, as evidenced by an increase in bone density and trabecular bone volume in the transgeni

87 derive the most benefit from measurements of bone density and treatments for bone diseases.

88 Differences in bone density and trunk lean body mass may account for so

89 Our objective was to examine changes in bone density and turnover with sustained, discontinued,

90 Antiretrovirals (ARVs) affect bone density and turnover, but their effect on risk of f

91 m binding protein D28k than normal mice, and bone density and volume increased in KO/TG compared with

92 genetics, dietary intake, estrogen use, and bone density) and of local biomechanical factors (such a

93 for viability, fertility, growth, appetite, bone density, and fat deposition and not likely to be a

94 ects of dietary changes on osteoporosis, low bone density, and frequent falls are unestablished.

95 for the associations among prior fractures, bone density, and incident fractures; and published stud

96 s with relatively higher local medial tibial bone density, and lateral bone marrow lesions occur in k

97 s, such as genetics, diet, estrogen use, and bone density, and local biomechanical factors, such as m

98 neck was twice that in patients with normal bone density, and the difference was statistically signi

99 uded terms for osteoporosis, osteopenia, low bone density, and the drugs listed in the key questions.

100 ffect growth, cellular and humoral immunity, bone density, and wound healing.

101 It has been suggested that changes in bone density are not surrogates for reduction in fractur

102 ts in whom both hypercalciuria and decreased bone density are present.

103 ing normal basal bone osteoclast numbers and bone density, are resistant to physiological and patholo

104 ent instruments are modest predictors of low bone density (area under the curve, 0.13 to 0.87; 14 ins

105 Cetaceans utilize low bone density as a buoyancy control mechanism, but the un

106 Using densitometry to monitor changes in bone density as a measure of therapeutic efficacy has be

107 model, the mice treated GNPs-ALD had higher bone density as compared to other OVX mice groups.

108 For every 1-unit increase in bone density as measured by pDEXA t-score at proximal an

109 QCT) was performed to measure the volumetric bone density as the most reliable parameter in vertebral

110 Condensation increased interfacial bone density, as measured by a significant change in bon

111 L3 and L4 vertebral mineral bone density, assessed by dual-energy x-ray absorption,

112 le no differences were found in radiographic bone density assessments.

113 ic acid decreases bone turnover and improves bone density at 12 months in postmenopausal women with o

114 as associated with a dose-related decline in bone density at both the total hip and the trochanter of

115 phy (microCT) analysis revealed an increased bone density at the bone-to-implant interface in the Osx

116 ed via total cross-sectional muscle area and bone density at the L3 vertebral level, compared with a

117 gressive declines in cortical and trabecular bone density at the peripheral skeleton.

118 Peri-implant bone density averaged 72.2% +/- 2.1% for coronal-load ve

119 G1 showed less bone density (BD) compared to G2.

120 percentage of defect fill (DF), newly formed bone density (BD), and new cementum formation (NCF) were

121 ion early in life has little effect on adult bone density because the juvenile bone is largely replac

122 an account for the different effect of LT on bone density between adult and pediatric populations in

123 We measured bone density (BMD), calciotropic hormones and bone turno

124 neral density (BMD) and estimated volumetric bone density (bone mineral apparent density [BMAD]).

125 is similar, HSL(-/-) mice maintain a higher bone density (bone volume/total volume 6.1%) with age th

126 to quantify fracture risk by measurement of bone density, bone quality, and risk factor algorithms.

127 cific foods or beverages and their effect on bone density, broadening understanding of eating pattern

128 loss has no clinically significant effect on bone density but slows bone turnover.

129 diopathic short stature (ISS) had no loss of bone density but were noted to have more vertebral abnor

130 with significant changes in measurements of bone density, but more studies of high doses and of ther

131 We measured bone density by dual-photon absorptiometry at base line,

132 The associations between bone density, CAL, and subgingival calculus require furt

133 relationship between serum testosterone and bone density change were detected.

134 o enhance detection of crestal or periapical bone density changes and to help evaluate caries progres

135 r percentage of trabecular bone and a higher bone density compared to controls (P < or =0.05) without

136 C/EBPalpha(+/-) mice exhibit an increase in bone density compared with C/EBPalpha(+/+) controls.

137 There was no measurable increase in bone density compared with that in unaffected individual

138 , we demonstrate low trabecular and cortical bone density contributing to lower volumetric bone miner

139 We measured trabecular bone densities, cortical bone densities, VAT areas, and

140 eased skeletal size, muscle mass, trabecular bone density, cortical bone geometry, and strength.

141 JRA patients had decreased tibia trabecular bone density, cortical bone size and strength, and muscl

142 ; total, cortical, and trabecular volumetric bone density; cortical area and thickness; and trabecula

143 en and women with baseline data was used for bone density cross-sectional analyses and combined with

144 shed tumor-mediated osteolysis, and lessened bone density decrement in mice injected with breast canc

145 CRHR1 polymorphisms may impact the risk of bone density deficits in patients treated with corticost

146 cup daily) was associated with a 2%-4% lower bone density, depending on site (P < 0.001), but the odd

147 including impairments of growth velocity and bone density), diagnostic and therapeutic interventions,

148 an tissue mass to account for differences in bone density did not significantly alter the results.

149 n a small but significant improvement in hip bone density, did not significantly reduce hip fracture,

150 Bone densities (dual x-ray absorptiometry [DXA]) were no

151 Raloxifene maintains bone density (estrogen-like effect) in postmenopausal os

152 In 2013 patients with serial bone density examinations, total hip BMD increased trans

153 The low trabecular bone density found in hemophilia is attributed to signif

154 Low bone density, fractures, and kyphosis complicate the liv

155 ssigned at year 2 to continue had additional bone density gains at the spine (mean, 2.3% +/- 0.7) and

156 P-2-treated sites showed better radiographic bone density, greater defect fill, and significantly mor

157 Most of those who lost bone density had started bisphosphonate therapy after tr

158 Decreased bone density has been increasingly associated with hyper

159 Women with low bone density have approximately a 40% to 50% reduction i

160 els and implications for overweight and poor bone density; high prevalence of obstructive sleep apnea

161 linkage disequilibrium, were associated with bone density in a sex-specific manner.

162 graphy analysis of adult femurs showed lower bone density in A2BAR KO mice as compared with WT.

163 ic conditions, thus implicating FGF23 in low bone density in cetaceans.

164 roducts may be more effective in maintaining bone density in equol-producing individuals.

165 cession, and significant changes in alveolar bone density in focal areas.

166 ng adulthood, assessing stimulant effects on bone density in growing children is of critical importan

167 ected controls, but with the highest loss of bone density in infected gp91(phox) KO mice.

168 mature fusion of the cranial sutures and low bone density in newborn FGFR3(G380R) mice.

169 idence supports that several medications for bone density in osteoporotic range and/or preexisting hi

170 trogen has been reported to improve cortical bone density in postmenopausal women with asymptomatic o

171 ptions which can be used for preservation of bone density in premenopausal patients with treatment-in

172 on with minimal fibrous tissue and increased bone density in rabbit radial defect models.

173 Statin use did not improve fracture risk or bone density in the Women's Health Initiative Observatio

174 Bone density in this range was termed "osteopenia" by a

175 letal quality and strength despite preserved bone density in type 2 diabetes, as well as the effects

176 es the expression of bone markers, increases bone density in vivo, and is used clinically in the mana

177 ial for stimulated osteoclast activation and bone density in vivo.

178 ificantly greater maxillary alveolar process bone density in women younger than 50 years of age than

179 ulating markers of bone turnover and reduced bone density in women.

180 ast lineage would affect bone resorption and bone density in young adult mice.

181 d long-term pharmacologic treatments for low bone density, including pharmaceutical prescriptions, ca

182 Ablation of COUP-TFII in mice led to higher bone density, increased muscle mass, and suppression of

183 ctured limbs, C57BL/6 mice had a decrease in bone density, increased subchondral bone thickness, and

184 or nuclear factor-kappa B ligand (RANKL) and bone density index (BDI) were determined stereologically

185 Low bone density is a growing concern in aging men with hemo

186 While peak bone density is similar, HSL(-/-) mice maintain a higher

187 that the effect of habitual tea drinking on bone density is small and does not significantly alter t

188 ion of FGF23, a gene associated with reduced bone density, is greatly increased in the cetacean liver

189 Bone density levels did not statistically differ between

190 also significantly associated with alveolar bone density loss (p < 0.0001) and alveolar bone height

191 have been investigated in the prevention of bone density loss and skeletal morbidity.

192 e negative role of hemophilic arthropathy in bone density loss.

193 s as the healing of broken bones, increasing bone density lost through aging, and strengthening the s

194 Loci associated with bone density/mass in both human and mouse were previousl

195 It also suggests that local changes in bone density may be a component of the disease process i

196 Finally, menopausal symptoms and bone density may be favorably influenced by phytoestroge

197 There is some indication that a higher bone density may not protect against fracture in these s

198 received osteoporosis treatment, final mean bone density (mean, 8.2 years after first scan) was aver

199 one density tests measured at various sites, bone density measured at the femoral neck by dual-energy

200 ip, posterior-anterior spine, and total-body bone density measured by using dual-energy x-ray absorpt

201 a for the diagnosis of osteoporosis based on bone density measurements have become apparent.

202 Although results of the bone density measurements were not significantly differe

203 rmative regarding implant failure than pDEXA bone density measures obtained at peripheral bones.

204 ing such osteoporosis-related factors as low bone density, moderate and severe prevalent vertebral fr

205 py-induced ovarian failure should have their bone density monitored and treatments to attenuate bone

206 Recommendation 4: ACP recommends against bone density monitoring during the 5-year pharmacologic

207 inistration of the two agents would increase bone density more than the use of either one alone.

208 osteoporosis (n = 30) and those with normal bone density (n = 29).

209 Recipients with normal bone density (n=24) were enrolled as controls.

210 one defect extension (RBDE); 2) newly formed bone density (NFBD); 3) total callus area (TCA); 4) oste

211 orse oral bone loss, in general, but neither bone density nor oral infection was significantly associ

212 temic risk factors include obesity; bone and bone density; nutrients, particularly those that functio

213 e of this study was to determine: (1) if the bone densities of the maxillary and mandibular alveolar

214 ontrol group showed a mean histomorphometric bone density of 34.25% +/- 10.02, while samples from the

215 after transplantation, the fracture rate and bone density of patients in each group were reassessed a

216 ancer drug, keoxifene, was found to maintain bone density of rats (estrogenic action) while simultane

217 e of 0.25 mg/d of 17beta-estradiol increased bone density of the hip, spine, and total body, and redu

218 ibular alveolar processes are related to the bone density of the spine, hip, or radius in healthy wom

219 d classify compression fractures and measure bone density of thoracic and lumbar vertebral bodies on

220 tive rate, as well as to calculate vertebral bone density, on CT images.

221 oped to assess clinical risk factors for low bone density or fractures have moderate to high sensitiv

222 approximately 15 years for women with normal bone density or mild osteopenia, 5 years for women with

223 prevent fractures in men and women with low bone density or osteoporosis.

224 eased odds of 1- and 2-year loss of alveolar bone density (OR = 1.98; P = 0.0001) in the placebo grou

225 studies, results of the WHI, and trials with bone density outcomes.

226 erapy (E/HRT) has beneficial effects on oral bone density over 3 years and that calcium and vitamin D

227 height (P <0.01), increased ridge width and bone density (P <0.01), enhanced 7-day prostaglandin E2

228 Extra-arterial pathology included low bone density (P<0.001); early onset degenerative spine d

229 tion of an Ezh2 inhibitor modestly increases bone density parameters of adult mice.

230 Deficits in spine bone density persisted after correcting for small bone s

231 mutations and its relationship to increased bone density phenotypes.

232 ate FRAX scores using data from the Manitoba Bone Density Program database of all women and men 40 ye

233 al women may serve as a surrogate measure of bone density, reflecting long-term lower estrogen levels

234 ors examined cross-sectional associations of bone density-related factors with blood lead levels amon

235 lations between VAT, muscle attenuation, and bone densities remained significant at -0.250, -0.119, a

236 Lateral lumbar spine and hip bone density remained stable or improved in 65% and 86%

237 ed phenotypes of this animal and the reduced bone density reported here parallel those of Cushing syn

238 /- 4.0% and 0.7 +/- 4.7%, in spine and femur bone density, respectively (p < or = 0.001 for the spine

239 ulatory mechanisms and cause higher or lower bone density, respectively.

240 and increased separation; the lower cortical bone density results from thinner cortices, whereas cort

241 tenuation as well as trabecular and cortical bone densities revealed negative correlations with BMI,

242 Bone density scans (dual-energy x-ray absorptiometry [DE

243 Bone density scores did not influence likelihood of PTx

244 Hemogram, lipids, and bone density should be periodically assessed in treated

245 ntakes, as well as circulating magnesium, on bone density status and fracture risk in an adult popula

246 dition, Ocy-PPARgamma(-/-) mice exhibit more bone density, structure, and strength by uncoupling bone

247 positron emission tomography (35.9%-53.6%), bone density studies (6.3%-20.0%), echocardiograms (5.0%

248 Bone density study performed 6 months earlier was normal

249 The Weight Loss, Protein and Bone Density Study was conducted from 2008 to 2011 in 32

250 In the MRL/MpJ mice, no differences in bone density, subchondral bone thickness, or histologic

251 , several studies of soy supplementation and bone density suggest that soy products may be more effec

252 ative association between BMI and muscle and bone densities, suggesting fat infiltration into these t

253 knees with relatively higher lateral tibial bone density, supporting the hypothesis that local BMD r

254 About half of postmenopausal women have a bone density T score at the femoral neck between -1.0 an

255 oups were similar in age, sex, CF mutations, bone density T scores, renal function, and body mass ind

256 role of risk factor assessment and different bone density techniques, frequency of screening, and ide

257 ave attempted to restrict the candidates for bone density testing.

258 t-term risk for fracture can be estimated by bone density tests and risk factors, and that fracture r

259 Among different bone density tests measured at various sites, bone densi

260 the effectiveness of risk factor assessment, bone density tests, or treatment were included.

261 ion was associated with a small reduction in bone density that did not translate into an increased ri

262 these two fates may be key to the decreased bone density that occurs with aging.

263 n who were 46 to 85 years of age and had low bone density to receive alendronate (10 mg daily; 28 men

264 ypoglycemia, as well as reduction of mineral bone density, trabecular bone content, and subcutaneous

265 RT6-KO) mice display loss of muscle, fat and bone density, typical characteristics of cachexia.

266 MD monitoring and management, posttransplant bone density typically remains stable or improves with m

267 Two repeated measurements of bone density units in the bones of 3 different hands dif

268 utilizing gray-scale intensity to calibrate bone density units per mm3, which made possible comparis

269 nges in serum biochemical values, trabecular bone density using micro-computed tomography, bone histo

270 measured trabecular bone densities, cortical bone densities, VAT areas, and subcutaneous adipose tiss

271 Hip bone density was 1.06 percent higher in the calcium plus

272 Bone density was assessed by dual energy x-ray absorptio

273 The increased bone density was associated with an increased bone forma

274 Bone turnover was lower, and bone density was higher, in obese people.

275 Bone density was lower in males (P = .001), in nonblack

276 In a subcohort (n = 5,022), bone density was measured and osteoporosis determined (n

277 Bone density was measured at the hip.

278 lth Initiative Observational Study, systemic bone density was measured at the spine, hip, forearm, an

279 Bone density was measured at three WHI centers.

280 Systemic bone density was measured by dual-energy x-ray absorptio

281 Bone density was measured by dual-energy X-ray absorptio

282 Bone density was measured using quantitative computed to

283 The interdental bone density was not affected in the absence of enamelin

284 Bone density was not decreased.

285 Bone density was remeasured 1 year after transplantation

286 ression of circulating IGF-I; however, total bone density was significantly reduced.

287 Mean bone density was significantly superior in the test grou

288 n; median, 0.5 years after transplantation), bone density was slightly below average for age and sex

289 Femur bone density was unchanged in mice heterozygous for Drp1

290 fort to identify genetic factors influencing bone density, we characterized a family that includes in

291 pine, total hip (and subregions), and radius bone densities were determined by dual-energy x-ray abso

292 lar bone loss (ABL) and lower interradicular bone density were detected in ligated molars in the CSI+

293 hormone binding globulin, gonadotropins, and bone density were measured and prednisone and CsA doses

294 alkaline phosphatase, 24-h urine calcium and bone density were performed.

295 influences of age, body mass index, and hip bone density were taken into account.

296 We finally argue that bone density, which is currently the most routinely used

297 ifferentiation and favors the maintenance of bone density with aging.

298 Alendronate (ALN) increases alveolar bone density with systemic use and, has been found to in

299 The LRP5V171 mutation causes high bone density, with a thickened mandible and torus palati

300 can (mean, 2.7 years after first scan), mean bone density Z scores have increased (lumbar spine, -0.2